Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumor Dendritic Cell Injection with OK-432 in Pancreatic Cancer
NCT00795977Phase 2Unknown
- Sponsor
- Fukushima Medical University
- Start
- Nov 2003
- Primary completion
- Nov 2011
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ACT2001 and streptococcus pyogenes preparation in pancreatic cancer (PC), sponsored by Fukushima Medical University. Primary endpoints: Maximally Tolerated Dose at 2 years and Dose Limiting Toxicities at 2 years. Status: unknown.
02
Drugs
ACT2001streptococcus pyogenes preparation
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00795977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00795977.